Please assess the completion status of the following clinical trial:

Trial Title: A Trial of NT-I7 in COVID-19 (SPESELPIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals must meet all of the following criteria to be included in the study:~* Laboratory-confirmed SARS-CoV-2 infection as determined by either a documented positive molecular assay/ other commercial or public health assay in any specimen collected \< 5 days prior to screening or a documented positive molecular assay ≥ 5 days prior to screening and confirmed by polymerase chain reaction (PCR) at screening.~* Illness of any duration with oxygen saturation \> 93% at room air, heart rate ≤ 100 beats per minute at rest, and no evidence of respiratory distress with respiration rate \< 20 breaths per minute.~* Able to provide informed consent.~* Aged ≥ 19 and ≤ 75 years.~* Absolute Lymphocyte Count \<1,500 lymphocytes/µL.~* Avoid becoming pregnant or impregnate a partner through 90 days after study agent administration. Females must agree to 2 methods of contraception, and males to at least one method of contraception.~* Not participate in any other clinical trial for an investigational therapy through day 30.~Exclusion Criteria:~* Moderate to severe hypoxic respiratory failure requiring supplemental oxygen at rest, mechanical ventilation, ECMO, or any other noninvasive ventilation modality.~* CRP \>15 mg/L or D-dimer \> 0.75 µg/mL.~* Estimated glomerular filtration rate (eGFR) \< 40 mL/min/1.73m2, or requiring dialysis.~* AST/ALT \> 3-times ULN, or total bilirubin \> 1.5 times ULN (except if due to Gilbert's syndrome).~* Pregnancy or breastfeeding.~* Use of systemic corticosteroids or immunomodulant within 4 weeks prior to screening.~* Receipt of an investigational agent or investigational use of a licensed agent within 16 weeks prior to screening.~* HIV infection or underlying history of known or unknown primary or acquired immunodeficiency associated with lymphopenia and/or recurrent opportunistic infections.~* Autoimmune disease requiring systemic treatment EXCEPT for vitiligo or endocrine disease (such as diabetes, thyroid disease, and adrenal disease) controlled by replacement therapy.~* Malignancy requiring treatment 1 year prior to screening.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NT-I7 (Type: EXPERIMENTAL): NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).